Your editor has been looking forward to the approval of the new injectable cyclooxygenase 2 (COX-2) nonsteroidal anti-inflammatory drug (NSAID) parecoxib for use in the perioperative period as a substitute for the non-selective injectable NSAID ketorolac, which inhibits platelet aggregation. Additionally, I have taken comfort that as I grow older and eventually may need pain relief for my stiff joints, I could depend on the oral COX-2 NSAIDs for safe and effective pain control. Now both of those options appear to be clouded.
The Food and Drug Administration (FDA) has issued an advisory opinion because of recently released data from